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Major Depressive Disorder (MDD) is a mental illness that affects millions of people
worldwide. People diagnosed with MDD are often prescribed antidepressant drugs. Most
antidepressants increase levels of serotonin (5-hydroxytryptamine, 5-HT) in the synapses
between neurons. Selective-serotonin reuptake inhibitors (SSRIs), one class of antidepressants,
do this by inhibiting the reuptake of serotonin released into the synapse. Serotonin neurons from
the brainstem raphe nuclei affect a wide range of areas throughout the brain. Among these areas
is the ventral pallidum (VP), located in the basal forebrain. Citalopram, an SSRI, has been found
to increase the firing rate of action potentials of neurons in the VP of rats. The VP also projects
to areas that are thought to be involved with MDD.
A novel antidepressant, vortioxetine, has been developed that has multimodal actions.
Vortioxetine inhibits the serotonin transporter as previous SSRI drugs do, but also is a 5-HT1A
receptor agonist, 5-HT1B receptor partial agonist, and a 5-HT1D, 5-HT3, and 5-HT7 receptor
antagonist. In the present study, we attempted to investigate the effects of vortioxetine on
neuronal activity in the VP of urethane-anesthetized rats through extracellular single-unit
electrophysiological techniques. We also measured heart rate and respiration rate, as the 5-HT
system is closely related to cardiac and respiratory function. We hypothesized that vortioxetine

would increase the frequency of action potentials in the VP and decrease cardiac activity and
respiration rate, as citalopram did. However, the multiple actions of vortioxetine could produce
qualitatively or quantitatively different effects from citalopram. It was found that increasing
doses of vortioxetine slightly increased, and then dramatically decreased heart rate in the
majority of rats tested. Vortioxetine most frequently increased respiration rate in the rats
examined. The results of this study are compared to citalopram and assist in further
understanding of the actions of vortioxetine as an effective and novel antidepressant.

KEYWORDS: Vortioxetine; Ventral Pallidum; Major Depressive Disorder, 5-HT1A agonist,
electrophysiology
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CHAPTER I: BACKGROUND AND REVIEW OF RELATED RESEARCH
Major Depressive Disorder
Major Depressive Disorder is a mental illness that affects over 350 million people
worldwide (Marcus et al., 2004) and is characterized by depressed mood, anhedonia, sleep
disturbances and apathy, among many other symptoms. Most antidepressants increase levels of
serotonin (5-hydroxytryptamine, 5-HT) in the synapses between neurons. It is well-known that
selective-serotonin reuptake inhibitors (SSRIs) increase 5-HT in synapses by decreasing the
amount of 5-HT that is taken back up into the presynaptic neuron, thereby increasing 5-HT’s
presence in the synapse and magnifying its effects. Thus, when antidepressants are administered,
5-HT neurotransmission is enhanced by delayed clearance of serotonin. Though the development
of SSRIs is a major progression in the treatment of depression, there are still problems associated
with this class of antidepressants. For example, SSRIs have a similar issue as tricyclic
antidepressants, in that there is a period of time prior to clinical improvement, known as
therapeutic lag. Also, approximately one-third of depressed patients do not respond favorably to
SSRIs or other antidepressants (Blier & Montigny, 1999). Fortunately, new antidepressants are
being developed every year to combat these issues.
5-HT Receptors
Antidepressants cause their therapeutic effects in part by increasing serotonin in the
synapses of the brain, which then acts on various 5-HT receptors that exist in many areas. 5-HT
receptors are located throughout the brain and are expressed on both excitatory and inhibitory
neurons. The resulting action on the neuron is largely dependent on which 5-HT receptors are
expressed by the neuron, among other factors (Leiser et al., 2015). Therefore, the type of 5-HT
receptor that is present on the neuron is vital in understanding the actions of 5-HT.
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There are many subtypes of 5-HT receptors, including 5-HT receptors one through seven.
The 5-HT1 receptor family, including 5-HT1A and 5-HT1B receptors, are inhibitory receptors.
Researchers found that within the dorsal raphe nucleus (where 5-HT neurons originate), there is
a high density of 5-HT1A receptors (Pompeiano et al., 1992) that are found exclusively on cell
bodies and dendrites of neurons (Riad et al., 2000). This location makes these receptors ideal
candidates to be both autoreceptors and heteroreceptors (Riad et al. 2000). While 5-HT1A
agonists can produce a wide range of effects (Leiser et al., 2015), both 5-HT1A autoreceptors and
heteroreceptors seem to decrease the firing rate of neurons in various parts of the brain (Chaput
and Montigny, 1988). 5-HT1A receptors on the cell body of neurons containing 5-HT
hyperpolarize the membranes of the neurons by opening potassium channels (Blier and
Montigny, 1999). SSRIs and 5-HT1A agonists induce an initial reduction in the firing of 5-HT
neurons as they increase the activation of the somatodendritic 5-HT1A autoreceptor (Blier and
Montigny, 1983). Stimulation of postsynaptic 5-HT1A receptors by 5-HT or direct 5-HT1A
agonists produces a similar hyperpolarization and inhibition of activity (Haddjeri et al., 1998).
Similar to 5-HT1A receptors, 5-HT1B receptors can be both autoreceptors and
heteroreceptors and can cause inhibitory activity in neurons. They are thought to be located on
the presynaptic terminals of 5-HT neurons (Sari, 2004). Researchers found that within both the
substantia nigra and the globus pallidus, 5-HT1B receptors were also found on the membrane of
preterminal axons. This location suggests that 5-HT1B receptors mediate neurotransmitter release,
because these receptors are able to mediate 5-HT induced changes in the conduction of the axon
(Riad et al., 2000). In both cases, these receptors control the inhibition of 5-HT release or another
neurotransmitter in various areas of the brain (Engel et al., 1986).
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There is much less known about 5-HT1D receptors than 5-HT1A or 5-HT1B receptors.
However, researchers have shown that activation of 5-HT1D receptors in the dorsal raphe nuclei
decreases the amount of 5-HT around the cell bodies that is released by electrical stimulation
(Davidson et al., 1995). This activation did not directly modulate firing activity, however
(Roberts et al., 1997).
5-HT3 receptors are excitatory receptors and seem to be located postsynaptically (Leiser
et al., 2015). The 5-HT3 receptor is thought to have a role in cognition, such as memory,
attention, and processing speed (Ladefoged, 2018).
5-HT7 receptors are excitatory receptors and seem to be expressed on GABAergic
neurons (Vysokanov et al., 1998). The activation of 5-HT7 receptors creates a positive feedback
loop, as it decreases GABA release, which disinhibits 5-HT neurons, resulting in an increased
level of synaptic 5-HT (Roberts et al., 2004). In conclusion, 5-HT is able to modulate neural
circuits in many ways through activating its various receptor subtypes.
Ventral Pallidum
5-HT neurons that originate in the brainstem raphe nuclei affect a wide range of areas
throughout the brain. For example, 5-HT neurons in the dorsal raphe nucleus project to areas in
the basal forebrain, including the ventral pallidum (VP) and overlapping nucleus basalis.
Consequently, 5-HT has been detected in the VP using microdialysis studies in rats (Sizemore,
2000). In turn, the VP projects to the raphe nuclei, and synapses onto dorsal raphe nuclei 5-HT
neurons (Pollak-Dorocic et al., 2014).
The VP’s main function is its role in processing and executing motivated behaviors. It
regulates motor functions that lead to the obtaining of a reward. The VP has shown to be an area
important for self-stimulation, in that animals will deliver an electrical stimulus to the VP in
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order to feel a sense of obtaining a reward (Panagis et al., 1995). It is also involved with drugseeking behavior and addiction. It is also thought to be important for emotion processing and
have a role in many psychiatric disorders, such as depression (Root, Melendez, Zaborszky, &
Napier, 2015).
A majority, around 80%, of the neurons in the VP are GABAergic neurons (Zahm et al.,
1985). GABAergic inputs can be modulated by the different types of 5-HT receptors (Leiser et
al., 2015). The VP and nucleus basalis also contain cholinergic neurons. Cholinergic neurons in
the VP provide a large amount of input to the amygdala, a major area responsible for emotions
(Carlsen et al., 1985). The dorsal raphe nuclei project to these cholinergic neurons in the nucleus
basalis (Jones and Cuello, 1989).
Regarding noncholinergic neurons, 5-HT applied to these cells in the guinea pig nucleus
basalis in vitro hyperpolarized most of the neurons in two out of three groups of cells
pharmacologically characterized by their responses to noradrenaline and muscarine (Fort et al.,
1998). However, 5-HT has been reported to depolarize noncholinergic neurons within the rat VP
in an in vitro study (Bengtson et al., 2004).
Regarding cholinergic neurons within the guinea pig nucleus basalis, 5-HT and 5-HT1A
agonists in vitro produced a hyperpolarization in 26 out of 31 neurons and in 6 out of 6
experiments conducted, respectively, suggesting that 5-HT and 5-HT1A receptors inhibit activity
within the nucleus basalis (Khateb et al., 1993). Similarly, 5-HT hyperpolarizes cholinergic
neurons within the rat VP in vitro (Bengtson et al., 2004).
Heidenreich and Napier (2000) conducted an experiment in anesthetized rats
investigating the effects of activating 5-HT1A and 5-HT1B receptors on VP firing rate in vivo
using the 5-HT1A agonist 8-OH-DPAT, the 5-HT1B agonist CP-94253, and the non-selective 5-
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HT agonist TFMPP. They recorded baseline activity in the VP in rats and then injected rats with
increasing doses of 8-OH-DPAT, CP-94253, or TFMPP. Neuronal responses were considered
significant when firing rate was changed by at least 20% from baseline. Researchers found that
8-OH-DPAT caused both increases and decreases in VP firing rate; however, increases in firing
rate were observed with lower doses. They also found that four neurons displayed a biphasic
response. CP-94253 most often produced no change in firing rate. Their last finding was that
TFMPP dose-dependently decreased neuronal activity in the VP. From these results, researchers
were able to conclude that 5-HT neurotransmission plays a role in regulating neuronal firing rate
in the VP.
As with direct agonists, it is possible for antidepressants to modify the firing rate of the
VP as well. Morrison and Heidenreich (2010) conducted an experiment investigating the effects
of citalopram, an SSRI, on VP neuronal activity as well as heart rate and respiration rate in
anesthetized rats. They recorded action potentials from VP neurons using electrophysiological
procedures, with neural responses to citalopram considered significant when activity changed by
at least 20% from basal levels. Their main finding was that citalopram primarily increased the
firing rate of the majority of VP neurons. They also found the citalopram decreased heart rate
and respiration rate in the majority of rats tested. Morrison and Heidenreich’s (2010)
fundamental conclusion from their experiment was that the 5-HT system influences VP neuronal
activity, as well as respiration and heart rate, in rats and that this is altered by antidepressants.
Nucleus Accumbens
There are several brain structures that project to the VP and affect its activity. Included in
these areas are the dorsal raphe nucleus, as previously mentioned, as well as the nucleus
accumbens. The nucleus accumbens represents the largest input to the VP (Chrobak and Napier,
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1993). Like the VP, the nucleus accumbens is thought to play a role in MDD, as well as have a
hand in motivation and reward mechanisms. It has been suggested that the dysfunction of the
nucleus accumbens produces anhedonia in MDD patients (Shirayama and Chaki, 2006). Since
the motivation-reward circuit is malfunctioning, it seems inevitable that a diminished interest or
pleasure in once preferred activities would develop. There are also serotonergic afferents to the
nucleus accumbens, which are thought to play a role in motivation and stress (McEwen et al.,
1993), both of which can be involved with symptoms of depression.
The nucleus accumbens contains GABA and cholinergic interneurons, but mostly it
contains efferent GABAergic projection neurons (Meredith et al., 1993). GABA neurons from
the nucleus accumbens core project to the VP, the ventral tegmental area, hypothalamus, and the
amygdala (Meredith et al., 1993). The GABAergic projection neurons are regulated by
serotonergic afferents from the dorsal raphe nucleus (Shirayama and Chaki, 2006). Nucleus
accumbens shell and core projections to the VP can synapse onto cholinergic neurons as well
(Grove et al., 1986).
In the shell of the nucleus accumbens, 5-HT has mostly inhibitory activity on GABA
neurons (Van Bockstaele et al., 1996). It has also been observed that 5-HT and GABAergic
terminals converge onto cholinergic neurons (Van Bockstaele, 1996). This led researchers to
believe that 5-HT has an inhibitory effect on cholinergic neurons and a disinhibition effect for
GABAergic neurons in the nucleus accumbens (Shirayama and Chaki, 2006).
Serotonergic activity regulates dopamine release in the nucleus accumbens. It has been
reported that application of 5-HT into the nucleus accumbens stimulates the release of dopamine
(Parsons and Justice, 1993). Therefore, it has been suggested that the faulty regulation of
forebrain dopamine neurotransmission by midbrain 5-HT and 5-HT2C receptors contributes to
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MDD (Di Matteo et al., 2001). Evidence of this was observed when researchers showed that with
the chronic administration of antidepressants, the 5-HT-dopamine system increased dopamine in
the nucleus accumbens (Zangen et al., 2001). 5-HT receptor subtypes are found all throughout
the nucleus accumbens (Pazos and Palacios, 1985) and are also involved in the dopaminergic
system. For example, the activation of 5-HT1A and 5-HT3 receptors causes an increase in
dopamine release within the nucleus accumbens (Parsons and Justice, 1993; Campbell and
McBride, 1995). In addition, it was discovered that 5-HT inhibited dopamine-sensitive nucleus
accumbens neurons that receive input from parafascicular nucleus of the thalamus by activation
of the 5-HT1A receptor (Nagaoka et al., 1998). Activation of this 5-HT1A receptor in the nucleus
accumbens is thought to produce antidepressant effects seen with 5-HT1A agonists, such as
buspirone (Nagaoka et al., 1998). The VP, the dorsal raphe nucleus and the nucleus accumbens
are all connected and can have their firing rates altered by the administration of numerous
serotonergic drugs.
Vortioxetine
A new antidepressant, vortioxetine, was approved for treatment for MDD in 2013.
Similar to citalopram, vortioxetine also blocks the reuptake of 5-HT, as it was found that
vortioxetine dose-dependently occupies the serotonin transporter (SERT) (Pehrson et al., 2012).
This drug can exert its antidepressant effects at just 50% occupancy of the SERT, while other
antidepressants require 80% occupancy (Sanchez et al., 2015; Meyer et al., 2004). It also showed
positive effects during tests in animal models of depression such as the forced swim test
(Guilloux et al., 2013) and has been found to significantly increase extracellular 5-HT levels in
rats in the ventral hippocampus, medial prefrontal cortex, nucleus accumbens, and the dorsal
raphe nuclei (Pehrson et al., 2013; Pehrson et al., 2012). Additionally, in a study by Eskelund et
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al. (2017), researchers administered vortioxetine in rat depression models for two weeks and
found that vortioxetine reduced 5-HT in the brain, as well as 5-HIAA, a metabolite of 5-HT. This
result is most likely due to the reduced activity of the serotonin transporter, leading to decreased
serotonin in the presynaptic neuron. They also found that, at therapeutic doses, vortioxetine
reduced levels of the neurotoxin, quinolinic acid (QUIN), which has been shown to be positively
correlated with the severity of depression symptoms in depressed patients (Guillemin, 2012;
Eskelund et al., 2017). In all brain regions, QUIN was reduced by 29%, and in rat plasma, QUIN
decreased by 50% (Eskelund et al., 2017).
Vortioxetine, however, is considered a multimodal antidepressant, in that is has several
mechanisms of action and acts on many of the 5-HT receptors. It is a 5-HT1A receptor agonist, a
5-HT1B receptor partial agonist, and a 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist. These
additional mechanisms of action are thought to have additional clinical benefits relative to other
SSRIs, such as improved cognitive function (Gonda et al., 2018), especially through the 5-HT3
receptor (Ladefoged, 2018).
Vortioxetine’s antidepressant effects seem to result from its activation of 5-HT1A and 5HT3 receptors, as well as the subsequent effect on GABAergic transmission (Gonda et al., 2018).
This effect is not found in any other antidepressants. In an electrophysiological study by Betry et
al. (2013), researchers found that after acute administration of vortioxetine, the firing rate of 5HT neurons in the dorsal raphe was dramatically suppressed. Researchers believe this is due to
the increased availability of synaptic 5-HT resulting from both the inhibition of the 5-HT
transporter and the activation of the various receptors. Researchers also discovered that when
researchers administered a 5-HT1A antagonist, the effect was reversed. Bétry et al. (2013) also
found that after chronic administration of vortioxetine, the 5-HT1A receptor becomes
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desensitized, and normal firing activity resumes after just 3 days (similar to SSRIs, however,
with SSRIs, it takes two to three weeks for firing activity to return to normal) (Blier and
Montigny, 1983). Researchers have also found that vortioxetine increased the tonic activation of
5-HT1A receptors on neurons in the hippocampus (Mansari et al., 2015), eventually resulting in
the receptors’ desensitization as well as increased 5-HT neurotransmission in the hippocampus.
There is a similar effect with the 5-HT1B receptors. These receptors are located on the
terminals of neurons, where they too have an inhibitory effect on 5-HT release. It has been found
that after chronic administration of SSRIs, the 5-HT1B receptor desensitizes, and returns 5-HT
transmission to normal levels (Blier and Bouchard, 1994). Mansari et al., 2015 found that 5-HT1B
receptors in the hippocampus desensitized with chronic administration of vortioxetine under
high, but not low, levels of activation. This provides evidence that vortioxetine does in fact, work
as only a partial agonist at the 5-HT1B receptor, as vortioxetine does not seem to affect the 5HT1B receptor 100% of the time, as a full agonist would.
By examining the occupancy of the 5-HT1B receptor in the ventral portion of the striatum,
researchers concluded that vortioxetine, but not an SSRI, has an effect on this area. Also
examined was the expression pattern of the 5-HT1A receptors in the septum. This region showed
an increase in connectivity with the somatosensory cortex after vortioxetine injections, but not
with an SSRI (Perez et al., 2018). Further, researchers examined a part of the hippocampus
known for expressing 5-HT1B receptors and found that vortioxetine increased connectivity
between the hippocampus and the medial prefrontal cortex, but an SSRI did not (Perez et al.,
2018). Perez et al. (2018) concluded from this experiment that vortioxetine has the ability to
affect connectivity of several different brain regions with 5-HT expression.
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Vortioxetine is also unique in that it initially works as a partial agonist at the 5-HT3
receptor, followed by intense antagonism (Dale et al. 2018) Vortioxetine’s activity as a 5-HT3
receptor antagonist has been shown to block the activity of GABAergic interneurons in the
ventral hippocampus, resulting in increased activity in that area. This mechanism is thought to
potentially have a therapeutic effect of the cognitive symptoms of MDD (Dale et al., 2014). The
5-HT3 receptor also has a high occupancy after vortioxetine administration, further increasing the
antidepressant effects of the drug (Sanchez et al., 2015; Meyer et al., 2004).
A study was conducted to determine resting-state functional connectivity after
vortioxetine administration. Researchers found that vortioxetine mostly affected connections
between association cortices and sensorimotor cortices as well as striatum-sensorimotor cortices;
vortioxetine also affected connections between the thalamus and hypothalamus, and the
hippocampus and retrohippocampus (Perez et al., 2018). It is clear that vortioxetine has
antidepressant effects and affects a wide range of brain areas through multiple actions.
Heart Rate
It is well-known that 5-HT and brainstem 5-HT neurons influence cardiac function. For
example, intracerebroventricular administration of 5-HT causes bradycardia in rats (Wang et al.,
1995). Studies have shown that antidepressants have the ability to decrease heart rate. In one
study, researchers found that low doses of citalopram decreased heart rate in rabbits (Bo et al.,
1987). Also, Morrison and Heidenreich (2010) found that a majority of rats tested displayed a
decreased heart rate after i.v. injections of citalopram. It is possible that the bradycardia observed
in these experiments is the result of 5-HT activation of the 5-HT1A receptor. The activation of
this receptor by 8-OH-DPAT given i.v. has previously been shown to decrease heart rate in rats
(Heidenreich & Kempel, 2005). It has been suggested that the vagus nerve may have a role in the
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bradycardia caused by 5-HT1A receptor activation. King and Holtman (1990) found that when the
vagus nerve is removed, there is no bradycardia observed after administration of 8-OH-DPAT.
The dorsal vagal motor nucleus (DVM) is innervated by brainstem 5-HT neurons
(Hopkins, 1987). The DVM gives rise to vagal motor neurons (Jordan, 1988) which regulate
heart rate (Steinbusch, 1981). These neurons are thought to have 5-HT1A receptors (Pazos &
Palacios, 1985) and iontophoretic application of 5-HT into the DVM activates vagal motor
neurons (Wang et al., 1995). Additionally, researchers found that the microinjection of 5-HT into
the nucleus ambiguous, another area thought to be partially responsible for heart rate, caused an
increase in activity in the vagal motor neurons, which, in turn, caused bradycardia (Jordan et al.,
1988). In sum, it seems likely that 5-HT1A receptors on the vagal motor neurons influence
cardiac activity, and their activation by 5-HT can reduce heart rate.
Though the relationship and mechanism(s) between heart rate and 5-HT is not completely
understood, there is evidence supporting the idea that 5-HT, antidepressants and 5-HT1A agonists
can affect cardiac function and heart rate, most likely by way of 5-HT1A receptor activation.
Respiration Rate
Much like with heart function, brainstem 5-HT neurons are also important for respiratory
activity. The rostral ventrolateral medulla, or RVL, (an important area controlling respiration)
receives 5-HT afferents from the dorsal raphe nuclei (Bianchi et al., 1995). However, there is
conflicting evidence regarding the connection between respiratory rate and 5-HT.
Researchers have found that 5-HT application to the RVL causes respiration rate to
increase, and then decrease. When the 5-HT2A antagonist ketanserin was administered, the
decreasing effect of 5-HT was blocked. This suggests that 5-HT2A receptor activation influences
respiratory rate. When researchers administered the 5-HT2 agonist, DOI, it caused increases in
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respiration rate (Onimaru et al., 1998). Additionally, the 5-HT2C receptor agonist m-CPP
(Edwards et al., 1990), the 5-HT1B agonist CP-94253, and the relatively non-selective 5-HT
agonist TFMPP (Heidenreich and Napier, 2000) all produce decreases in respiration rate.
Bo et al., (1987) found respiratory rate to decrease after the administration of citalopram
to awake rabbits. Morrison and Heidenreich (2010) found that a majority of rats tested with
citalopram showed a decrease in respiration rate, followed by a slight increase. Researchers
suggest that a possible reason for this slight increase after high doses is that small increases in 5HT will decrease respiratory rate, while greater increases in 5-HT has to ability to reverse the
effect.
It has been suggested that the 5-HT1A receptor plays a role in altering respiratory rate.
Onimaru et al. (1998) found that with the administration of a low-concentration dose of 8-OHDPAT into the RVL, respiration rate equally increased and decreased. However, at high
concentrations of 8-OH-DPAT, the respiration rate responses were mostly decreased from
baseline. However, other researchers have actually found the opposite effect. Heidenreich and
Kempel (2005) administered 8-OH-DPAT i.v. to anesthetized rats and found that respiration rate
increased. Finally, King and Holtman (1990) found that respiratory rate was not changed at all
after 8-OH-DPAT was applied to the ventral medulla.
It is clear that though the literature is conflicting, there is, indeed, evidence supporting the
idea that 5-HT, 5-HT receptor ligands, and antidepressants, can alter respiration rate.
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CHAPTER II: CURRENT STUDY
For the current study, we aimed to investigate the effects of vortioxetine on neuronal
activity in the VP, heart rate and respiration rate of urethane-anesthetized rats through
electrophysiological techniques.
We hypothesized that:
H1: Vortioxetine would increase the frequency of action potentials in the majority of neurons in
the ventral pallidum.
H2: Vortioxetine would decrease the heart rate in the majority of rats tested.
H3: Vortioxetine would decrease the respiration rate in the majority of rats tested.
Method
Subjects
The current study used 6 male Sprague-Dawley rats obtained from Envigo (Indianapolis,
IN). The rats weighed 275 grams to 450 grams and were housed in plastic tubs and allowed free
access to food and water for the duration of the study. All animals were cared for in accordance
with The Guide for the Care and Use of Laboratory Animals (8th edition) of the National
Institutes of Health. This research, including the protocols and methods, was approved by the
Institutional Animal Care and Use Committee (IACUC).
Materials and Procedure
First, single barrel glass electrodes were pulled to the proper size, the tips broken so the
diameter of the opening was 1-3μm, and were filled with 1% pontamine sky blue dye in a 2M
sodium chloride solution.
Rats were anesthetized with urethane (1.5 g per kg i.p.). Tests, such as a toe pinch, were
conducted to ensure that the animal showed no pain reflexes during the procedure. Rats were

13

then placed in a stereotaxic instrument equipped with a micromanipulator and secured with ear
bars. A catheter was placed in the femoral vein for drug solution administration, as well as the
maintenance of anesthesia. A metal clip was applied to the rat’s chest for the
electrophysiological recording of heart rate.
An incision was made in the scalp of the rat, exposing the skull. A hole was then drilled
in the skull over the ventral pallidum region, 0.5mm posterior and 2.2mm lateral to bregma,
determined by Paxinos and Watson’s (1986) rat brain atlas. Next, an electrode was lowered into
the brain of the rat until the tip was in place to record extracellular activity from a ventral pallidal
neuron, at an approximate depth of 6.8 to 8.0 mm. Activity throughout the duration of the
experiment was monitored using an amplifier and filter with a window discriminator and was
displayed with a digital storage oscilloscope. Action potentials would have been counted using
Spike2 software on a PC computer equipped with a Micro 1401 interface. Baseline heart rate
activity was recorded continuously for at least 5 minutes using Spike2 while respiration rate was
counted manually during 30 second intervals.
After baseline recordings, rats were injected i.v. with increasing doses of vortioxetine
(starting at 0.25 mg/kg) in either a 0.9% sodium chloride or a 10% cyclodextrin solution every 2
minutes. Heart rate and respirations per 30 second intervals were recorded after each dose, using
Spike2 software to analyze vortioxetine-induced effects. Changes in VP firing rate would have
been considered significant if firing rate changed by 20% or more from baseline levels, and
respiration and heart rate were considered significant if they changed by 3% or more from
baseline levels after 2 successive injections, the same criteria that Morrison and Heidenreich
(2010) used.
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After data collection, pontamine sky blue dye was ejected into the recording site. The rats
were given an approximately 0.3 ml dose of urethane and were transcardially perfused with 0.9%
sodium chloride and 4% paraformaldehyde in 0.1 M phosphate buffer. The brains were removed
and stored in a paraformaldehyde solution for 24 hours, and then a 20% sucrose solution until the
sectioning of the brain.
After 72 hours in sucrose, the brains were sectioned with a cryostat microtome at 40 μm
thick beginning at the anterior region of the VP. Brain sections were mounted onto slides and
dried. The sections were rehydrated, stained with neutral red, defatted with ethanol and xylene,
and then coverslipped. Microscopy allowed for confirmation of the proper location of recording
(in the VP). Data would have only been used if recordings were taken from VP neurons.
The cubic regression method (Pitts et al., 1990) was used to determine Emax and ED50
values, as in previous work (Heidenreich and Napier, 2000). Emax is the maximal response that
occurred for each rat. Its corresponding dose is simply the amount of the drug that is required to
cause Emax. E½max is 50% of Emax, and ED50 is the amount of drug required to cause
E½max. The cubic regression method is better in determining a best-fit function, as well as a
better method for defining Emax and ED50 values, than linear regression. Pearson correlation
coefficients and linear regression were used to examine the relationship between basal heart and
respiration rates and the ED50s of vortioxetine.
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CHAPTER III: RESULTS
We hypothesized that vortioxetine would increase activity in the majority of VP neurons
tested but were unable to collect data to test this hypothesis. We hypothesized vortioxetine would
decrease heart rate in the majority of rats tested. Data from this experiment support this
hypothesis. We hypothesized that vortioxetine would decrease respiration rate in the majority of
rats examined. Data from this experiment do not support this hypothesis.
Neural Activity
We were unable to collect neuronal electrophysiological data that was of a high enough
quality and for a sufficient duration to examine the effects of vortioxetine administration. Action
potentials were observed at the presumed depth of the VP but often were not of a sufficient
amplitude and signal-to-noise ratio to meet the standards for an acceptable recording. In some
rats, action potentials that were acceptable were observed only for a period of time that was too
short to perform data collection.
The difficulty in collecting neuronal recording data likely resulted from problems with
our electrodes. We tried several ways to improve the quality of electrodes. The settings on the
electrode puller were altered to determine if we could make better electrodes. This produced
electrodes that were either too high or too low in impedance to be usable for recordings in the
brain. It became necessary to use a different electrode puller. Unfortunately, the electrodes from
this puller were unable to record action potentials as the electrode would increase in impedance
shortly after entering the brain to the point that it was unusable. To combat this issue, we
performed an experiment to see if we could determine a puller setting that created electrodes that
did not increase in impedance in the brain. We soaked electrodes from different puller settings in
0.9% sodium chloride (to mimic the brain) for one hour and then measured their impedances.
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The setting of the electrodes that did not increase in impedance was noted and was used on all
subsequent electrodes. However, when the electrodes were inserted into the brain, they still
increased in impedance and were not usable. Finally, we changed the amplifier used with the
electrodes to determine if that was the cause of the lack of acceptable activity. This had no effect.
In sum, the experiment was performed without successful neuronal data collection. This
experiment could be conducted again with technical issues resolved to allow for the recording of
neural data.
Heart Rate
We recorded heart rate from 6 rats. Prior to the administration of vortioxetine, injections
of the vehicle solutions for vortioxetine were given as controls. In animals 1 and 2, vortioxetine
was dissolved in 0.9% sodium chloride. Because this solution was more of a suspension, a 10%
solution of cyclodextrin in water was used as a vehicle to create a true solution of vortioxetine
for animals 3 through 6. Thus, animals 1 and 2 were injected with sodium chloride vehicle only,
and animals 3 through 6 were injected with both the sodium chloride and cyclodextrin solutions.
The sodium chloride control injection altered heart rate in the 6 rats by an average 1.0% from
baseline, while the cyclodextrin injection increased heart rate by an average of 1.2% from
baseline in the 4 rats tested. These responses are below our criteria for a significant change in
heart rate, which must be met after at least two successive injections.
The responses in heart rate to vortioxetine are summarized in Table 1. We observed that
67% (4/6) of rats showed heart rate responses that slightly increased from baseline and then
decreased. In 1 of 6 rats (17%), heart rate only decreased. One of 6 rats (17%) showed no change
in heart rate.
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Table 2 shows the mean, standard deviation, and standard error of the mean for the five
heart rate responses that decreased, for each dose of vortioxetine, displayed cumulatively. There
was a small average increase in heart rate after 0.25, 0.5, and 1 mg/kg cumulatively. Heart rate,
on average, then returned to baseline, and then markedly decreased after 4, 8, and 16 mg/kg
cumulatively. These results are displayed in Figure 1.
Table 3 displays the mean, standard deviation, and standard error of the mean of the
average maximal response (Emax) value and its respective dose, as well as the E½max value and
its respective dose (ED50), for the five heart rate responses that decreased. The Emax for heart
rate was 84.2% of baseline, with a corresponding dose of 14.1 mg/kg. The average E½max was
92.1% of baseline, with a corresponding ED50 of 7.8 mg/kg. We also analyzed the correlation
between baseline heart rate and the ED50 value for the five heart rate responses that decreased.
There was no significant correlation (r = 0.05), as shown in Figure 2.
Respiration Rate
We recorded respiration rate from the same 6 rats that were used to observe heart rate. As
noted above, animals 1 and 2 were given control injections of sodium chloride only, and animals
3 through 6 were injected with both sodium chloride and cyclodextrin solutions prior to
vortioxetine. In the 6 rats, the sodium chloride control injection altered respiration rate by an
average 0.8% from baseline. The cyclodextrin injection changed respiration rate in 4 rats by an
average of 0.6%. These responses are below our criteria for a significant change in respiration
rate, which must be met after at least two successive injections.
The responses in respiration rate to vortioxetine are summarized in Table 1. We observed
that 50% (3/6) of rats had an increase in respiration rate after drug administration. In 1 of 6 rats
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(17%), respiration decreased, while the remaining 33% (2/6) of rats did not show a change in
respiration rate.
Table 2 shows the mean, standard deviation, and standard error of the mean for the 3
respiration rate responses that increased, for each dose of vortioxetine, displayed cumulatively.
The first and second dose (0.25 and 0.5 mg/kg cumulatively) did not alter respiration rate.
However, with the remaining doses, respiration rate increased. Two rats displayed a respiration
rate that tapered off after the last two doses, and one rat’s respiration rate plateaued during the
last 3 doses. The dose-response curve for these results is displayed in Figure 3.
Table 3 displays the mean, standard deviation, and standard error of the mean of the
Emax values and their respective dose, as well as the E½max value and ED50, for the three
respiration rate responses that increased. For respiration, the Emax value was 125.4% of
baseline, with a corresponding dose of 7.6 mg/kg. The E½max value was 112.7% of baseline,
with a corresponding ED50 of 1.4 mg/kg.
We also analyzed the correlation between respiration rate and the ED50 value for the
three respiration rate responses that increased. There was a negative correlation, r = -0.93;
however, this value was not significant (p = 0.25). These results are shown in Figure 4.
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CHAPTER IV: DISCUSSION
General Discussion
Our study showed that increasing doses of vortioxetine slightly increased, and then
dramatically decreased heart rate in the majority of rats tested. This finding supports our
hypothesis and is consistent with previous research. We also showed that increasing doses of
vortioxetine most frequently increased respiration rate in the rats examined. Respiration rate
increases did, however, show a trend of tapering off after the last two doses of vortioxetine.
Despite that, our respiration rate results differ from what we hypothesized.
Vortioxetine’s depressant effect on heart rate is consistent with its action as an SSRI and
Morrison and Heidenreich’s (2010) finding that the administration of the SSRI citalopram
reduced cardiac activity in anesthetized rats. The exact neural mechanisms for the alteration of
heart rate after antidepressant administration are unknown, but likely involve the activation of 5HT1A receptors. Since both vortioxetine and citalopram increase synaptic 5-HT in the brain
where it is able to activate 5-HT receptors, including the 5-HT1A receptor, we suggest a link
between the SSRI actions of vortioxetine and citalopram, the activation of 5-HT1A receptors and
regulation of heart rate.
This idea is supported by previous research linking 5-HT1A receptor activation and
reductions in heart rate. Heidenreich and Kempel (2005) that found that the administration of the
5-HT1A agonist 8-OH-DPAT decreased heart rate in anesthetized rats. Vagal parasympathetic
motor neurons in the DVM possess 5-HT1A receptors (Pazos & Palacios, 1985) and application
of 5-HT to the DVM results in bradycardia (Wang et al., 1995). Interestingly, vortioxetine’s
actions, not only as an SSRI but also as a direct 5-HT1A agonist, provides an additional
mechanism for the reduction in heart rate observed in our study.
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In addition to its predominantly depressant effect on cardiac activity, vortioxetine
produced slight but consistent increases in heart rate at the lowest doses tested. In this regard,
vortioxetine differs from citalopram, which produced only progressive reductions in heart rate
(Morrison and Heidenreich, 2010). As noted above, vortioxetine’s additional action as a 5-HT1A
agonist likely has a suppressant effect on cardiac activity. Thus, an increase in heart rate
probably relates to vortioxetine’s other properties as a 5-HT1B receptor partial agonist or 5-HT1D,
5-HT3, and 5-HT7 receptor antagonist. This experiment provides no evidence to distinguish
between these possibilities.
In the present study, vortioxetine produced an increase in breathing rate in the majority of
rats tested. This clearly represents a difference from the effects of citalopram, which consistently
decreases respiration rate (Morrison and Heidenreich, 2010). While both drugs are SSRIs,
citalopram is not a multimodal antidepressant and does not act on 5-HT receptors. In contrast,
vortioxetine is, in fact, a multimodal antidepressant, with direct actions at multiple 5-HT receptor
subtypes. We suggest that any of vortioxetine’s other actions, including its 5-HT1A agonism or 5HT1D, 5-HT3, and 5-HT7 receptor antagonism, could have caused the increase in breathing rate
observed with the current study.
One likely mechanism for vortioxetine’s effect on respiration concerns its action as a 5HT1A receptor agonist and the role of these receptors on breathing. Application of 8-OH-DPAT
into the RVL alters respiration rate (Onimaru, 1998). Furthermore, Heidenreich and Kempel
(2005) observed increases in breathing rate after i.v administration of 8-OH-DPAT. It is a
reasonable hypothesis that vortioxetine may have directly activated 5-HT1A receptors, similar to
8-OH-DPAT, to increase breathing in the present study. In contrast, vortioxetine’s action as a
partial 5-HT1B agonist appears unlikely to explains our results. Heidenreich & Napier (2000)
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found that i.v. injections of CP-94253, a 5-HT1B agonist, decreases respiration rate in
anesthetized rats. Finally, it is possible that vortioxetine’s action as a 5-HT1D, 5-HT3, and 5-HT7
receptor antagonist may have contributed to the increase in breathing rate we observed. I.v.
administration of TFMPP, a non-selective 5-HT agonist, decreases respiration rate in
anesthetized rats (Heidenreich & Napier, 2000). If 5-HT1D, 5-HT3 or 5-HT7 receptors are
tonically activated by endogenous 5-HT and function to reduce breathing rate, vortioxetine’s
actions as an antagonist could increase respiration.
In sum, it is a reasonable hypothesis that the additional receptor mechanisms of
vortioxetine contributed to the increase in breathing rate that lessened at high doses. The idea
that multiple effects of vortioxetine were involved seems likely. Two of our rats showed
respiration rate results that “tapered off” for the final two doses of vortioxetine, and one showed
a plateauing effect. The average dose for the mean Emax for respiration increases was less than
half of the highest cumulative dose administered. Respiration rate after higher doses of the drug
may reflect recruitment of additional actions, relative to that produced by the lower doses used.
In conclusion, the results of this experiment assist in determining if vortioxetine acts
mostly as an SSRI, like citalopram, or if its multiple actions make it unique in its effects. For
heart rate, vortioxetine produced responses similar to those expected of an SSRI. Regarding
respiration, vortioxetine differs notably from citalopram in its effects, typically producing an
increase (rather than a decrease) in breathing rate.
Limitations
The most significant limitation in our experiment was the inability to record
electrophysiological data from neurons and test our first hypothesis. The procedures we used are
generally considered standard techniques but are not without difficulty performing. Our belief is
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that the electrodes used in this experiment caused the majority of problems. While we tried a
number of ways to improve the electrodes and their usability, we were not completely successful.
However, this complication could be overcome in future work, and the first hypothesis in this
research investigated.
The sample size for our analysis of the effect of vortioxetine on heart activity and
breathing rate is small. While the results from the 6 rats examined seem unlikely to change
dramatically, a larger sample would provide more definitive and conclusive values for some
parameters. For example, there was a large (r = -0.93) but non-significant correlation between
basal respiration rate and the ED50 value of vortioxetine in the sample of 3 rats that increased
breathing rate. A larger sample size likely would determine if this correlation is statistically
significant and truly exists, or simply resulted from chance and limited observations.
Finally, future research on vortioxetine’s effects may benefit from the use of specific 5HT receptor agonists and antagonists to shed additional light on the mechanisms involved. The
ability of a receptor-selective drug to reverse the effect of vortioxetine may help determine the
most important and relevant action(s) in influencing heart rate and respiration.
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CHAPTER V: CONCLUSION
This experiment aided in determining vortioxetine’s effects on heart rate and respiration
rate in the anesthetized rat. In summary, increasing doses of vortioxetine increased and then
decreased heart rate, and increased respiration rate. It seems possible that the SSRI action of
vortioxetine is responsible for the decreased heart rate, and the other multiple actions of the drug
are responsible for the increased respiration rate. The results of the current research, as well as
previous studies, indicate that 5-HT1A receptor activation has a role in the regulation of heart rate
and respiration rate. However, regardless of the mechanism, it is clear that vortioxetine has the
ability to alter heart rate and respiration rate in rats.
The results of this study suggest possible mechanisms for alterations in heart rate and
respiration rate observed after the administration of drugs affecting the 5-HT system. In the near
future, this research may be important for developing other medications, especially
antidepressants. The results of this experiment should be considered in future research involving
further investigation of vortioxetine, as well as research involving 5-HT as it relates to heart rate
and respiration rate.
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APPENDIX A: TABLES
Table 1. Overall responses for heart rate and respiration rate after increasing doses of
vortioxetine. A criterion of 3% or greater change from baseline for two successive injections was
used to determine responses.
Animal #

Heart Rate

Respiration Rate

1

Decrease

Increase

2

No change

No Change

3

Increase/Decrease

Decrease

4

Increase/Decrease

Increase

5

Increase/Decrease

Increase

6

Increase/Decrease

No Change
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Table 2.
Mean, standard deviation, and standard error of the mean for the five heart rate responses that
decreased and the three respiration rate responses that increased after increasing doses of
vortioxetine ranging from .25-16 mg/kg cumulatively.
Cumulative
Dose
(mg/kg)

Heart Rate

Respiration Rate

Mean

Standard
Deviation

Standard
Error of
Mean

Mean

Standard
Deviation

Standard
Error of
Mean

0.25

103.5

6.4

2.9

100.5

5.2

3.0

0.5

104.1

5.8

2.6

102.7

9.0

5.2

1

103.1

7.4

3.3

111.5

13.2

7.6

2

100.4

7.8

3.5

116.4

16.6

9.6

4

96.2

11.5

5.1

126.3

9.2

5.3

8

90.1

11.1

5.5

121.7

10.4

6.0

16

84.4

8.6

3.8

116.4

10.2

5.9
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Table 3.
Mean, standard deviation, and standard error of the mean of Emax and E ½ max and their
respective doses for the five heart rate responses that decreased and the three respiration rate
responses that increased after increasing doses of vortioxetine ranging from .25-16 mg/kg
cumulatively.
Heart Rate

Respiration Rate

Mean

Standard
Deviation

Standard
Error of
Mean

Mean

Standard Standard
Deviation Error of
Mean

Emax

84.2

8.9

4.0

125.4

10.1

5.8

Emax dose

14.1

2.7

1.2

7.6

4.5

2.6

E 1/2max

92.1

4.5

2.0

112.7

5.1

2.9

ED50

7.8

4.2

1.9

1.4

0.7

0.4
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APPENDIX B: FIGURES
Figure 1. Dose-response curve for the five heart rate responses that decreased after
administration of increasing doses of vortioxetine (filled circles). The Emax value and ED50
value are also displayed (open squares).
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Figure 2. Correlation between baseline heart rate (beats/30 seconds) and ED50 for the five heart
rate responses that decreased after the administration of increasing doses of vortioxetine. The
correlation (r = 0.05) is not significant.

140

BASELINE HEART RATE (BEATS / 30 S)

130

120

110

100

90

80

70

60
1

10
ED50 OF VORTIOXETINE (mg/kg i.v.)

40

Figure 3. Dose-response curve for the three respiration rate responses that increased after
administration of increasing doses of vortioxetine (filled circles). The Emax value and ED50
value are also displayed (open squares).
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Figure 4. Correlation between baseline respiration (breaths/30 seconds) and ED50 for the three
respiration rate responses that increased after the administration of increasing doses of
vortioxetine. The correlation (r = -0.93) is not significant (p = 0.25).
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